Literature DB >> 31056691

Global and regional echocardiographic strain to assess the early phase of hypertrophic cardiomyopathy due to sarcomeric mutations.

Guillaume Baudry1,2, Nicolas Mansencal3,4, Amelie Reynaud5, Pascale Richard6, Olivier Dubourg3,4, Michel Komajda1,7, Richard Isnard1,8, Patricia Réant5, Philippe Charron1,8.   

Abstract

AIMS: Hypertrophic cardiomyopathy (HCM) is a genetic disease with delayed cardiac expression. Our objective was to characterize left ventricular (LV) myocardial strain by two-dimensional echocardiography in sarcomeric mutation carriers before the hypertrophic stage. METHODS AND
RESULTS: We studied 140 adults [derivation cohort (n = 79), validation cohort (n = 61)]. The derivation cohort comprised 38 confirmed HCM patients with hypertrophy (LVH+/Gen+), 20 mutation carriers without LV hypertrophy (LVH-/Gen+), and 21 healthy controls. LV global longitudinal strain was not different in LVH-/Gen+ compared with controls [20.6%, interquartile (IQ): 18.3/24.2 vs. 22.9%, IQ: 20.9/26.8] but was reduced in LVH+/Gen+ patients (14.1%, IQ: 11.8/18.5, P < 0.001). Regional peak longitudinal strain was significantly decreased in LVH-/Gen+ when compared with controls in four segments: basal anteroseptal (BAS) wall (P = 0.018), basal inferoseptal wall (P = 0.047), basal inferior wall (P = 0.006), and mid anteroseptal wall (P = 0.022). Receiver operating characteristic analysis identified that BAS strain <16.5% had a sensitivity (Se), specificity (Sp), positive and negative predictive values (PPV, NPV) of 57%, 90%, 82%, and 67%, respectively, to differentiate LVH-/G+ patients from controls. Similarly, the accuracy of a ratio between basal inferoseptal/basal anterolateral (BIS/BAL) strain <0.76 was 73%, 92%, 82%, and 64%, respectively (Se/Sp/PPV/NPV). In the validation cohort, the accuracy of BAS and BIS/BAL was 39%/93%/87%/57% and 55%/96%/95%/64% (Se/Sp/PPV/NPV), respectively, to differentiate the LVH-/Gen+ group from controls.
CONCLUSION: Regional longitudinal strain, but not global strain, was significantly reduced at the early stage of HCM before LV hypertrophy. This suggests that the inclusion of strain (BAS < 16.5%; BIS/BAL < 0.76) in the evaluation of HCM relatives would help identify mutation carriers and early LV abnormalities. Published on behalf of the European Society of Cardiology. All rights reserved.
© The Author(s) 2019. For permissions, please email: journals.permissions@oup.com.

Entities:  

Keywords:  diagnostic score; echocardiography; gene; hypertrophic cardiomyopathy; preclinical; strain

Mesh:

Year:  2020        PMID: 31056691     DOI: 10.1093/ehjci/jez084

Source DB:  PubMed          Journal:  Eur Heart J Cardiovasc Imaging        ISSN: 2047-2404            Impact factor:   6.875


  4 in total

1.  Could two-dimensional radial strain be considered as a novel tool to identify pre-clinical hypertrophic cardiomyopathy mutation carriers?

Authors:  Gloria Maria Santambrogio; Alessandro Maloberti; Paola Vallerio; Angelica Peritore; Francesca Spanò; Lucia Occhi; Francesco Musca; Oriana Belli; Benedetta De Chiara; Francesca Casadei; Rita Facchetti; Fabio Turazza; Emanuela Manfredini; Cristina Giannattasio; Antonella Moreo
Journal:  Int J Cardiovasc Imaging       Date:  2019-07-18       Impact factor: 2.357

2.  Are Myocardium Deformation Indices Influenced by Cardiac Load, Age or Body Mass Index?

Authors:  Vera Maria Cury Salemi; Marcelo Dantas Tavares de Melo
Journal:  Arq Bras Cardiol       Date:  2019-11-04       Impact factor: 2.000

3.  Usefulness of Longitudinal Strain Adjusted to Regional Thickness in Hypertrophic Cardiomyopathy.

Authors:  Sophie Urtado; Hélène Hergault; Stephen Binsse; Vincent Aidan; Mounir Ouadahi; Catherine Szymanski; Sophie Mallet; Marie Hauguel-Moreau; Robert Yves Carlier; Olivier Dubourg; Nicolas Mansencal
Journal:  J Clin Med       Date:  2022-04-08       Impact factor: 4.964

4.  Endovascular reversal of renovascular hypertension blunts cardiac dysfunction and deformation in swine.

Authors:  Shasha Yu; Kai Jiang; Xiang Y Zhu; Christopher M Ferguson; James D Krier; Amir Lerman; Lilach O Lerman
Journal:  J Hypertens       Date:  2021-03-01       Impact factor: 4.844

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.